Loading...
Nos encantaría que formes parte de nuestra comunidad. Únete a nuestro Discord para conectarte con nosotros y otros miembros!
- Ticker
- MVIR.ST
- Price
- 1.61
- Stock movement down
- -0.10 (-5.03%)
- Company name
- Medivir AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Capitalización del mercado
- 207.74M
- Valor de Ent
- -
- Precio/Ventas
- -
- Precio/Reservar
- -
- Rendimiento del div.
- -
- Crecimiento del div.
- -
- Años de crecimiento
- -
- Pago FCF
- -
- Seguimiento de P/E
- -
- P/E A plazo
- -
- PEG
- -
- EPS crecimiento
- -
- Rendimiento a 1 año
- -38.68%
- Rendimiento a 3 años
- -38.00%
- Rendimiento a 5 años
- -31.30%
- Rendimiento a 10 años
- -30.66%
Última actualización: 2025-09-17
DIVIDENDOS
MVIR.ST no paga dividendos
VALORACIÓN
Relaciones de valoración
Loading...
Datos de relaciones de valoración
| Seguimiento de P/E | - |
| Precio de OCF | - |
| Precio de FCF | - |
| Precio de EBITDA | - |
| EV a EBITDA | - |
Valoración (ventas/valor contable)
Loading...
Datos de valoración (ventas/valor contable)
| Precio de venta | - |
| Precio para reservar | - |
| EV a ventas | - |
FINANZAS
INFORMACIÓN SOBRE LAS ACCIONES
Gráfico de acciones
Loading...
Datos sobre el precio de las acciones
| Abierto | 1.97 |
| Máximo diario | 2.00 |
| Mínimo diario | 1.85 |
| Volumen diario | 182K |
| Máximo histórico | 190.06 |
| Estimación de analistas a 1 año | 20.71 |
| Beta | -0.23 |
| EPS (TTM) | - |
| Dividendo por acción | - |
| Fecha ex-div | - |
| Próxima fecha de beneficios | 6 Nov 2025 |
Potencial de desventaja
Loading...
Datos del potencial de desventaja
| MVIR.ST | S&P500 | |
| Caída del precio actual desde el máximo histórico | -99.03% | -1.06% |
| La mayor caída de precio | -99.35% | -56.47% |
| Fecha de la mayor caída | 7 Apr 2025 | 9 Mar 2009 |
| Caída promedio del máximo | -75.66% | -10.99% |
| Tiempo promedio para un nuevo máximo | 407 days | 12 days |
| Tiempo máximo hasta el nuevo máximo | 6471 days | 1805 days |
DETALLES DE LA EMPRESA
Mercado
207.74M
Categoría de Mercado
Small-cap
Descripción
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a clinical trial collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.
Empleados
10
Sitio web
Relaciones con inversionistas
-
Archivos de la SEC
CEO
País
Sweden
Ciudad
Tipo de acciones
-
CCC estatus
-
Frecuencia de Dividendos
-
EVENTOS Y PRESENTACIONES
EventosPresentaciones
Loading...
ENTENDER EL NEGOCIO
Loading...
NOVEDADES DE LA EMPRESA
Todas las novedadesComunicados de prensa
Medivir AB (STU:MVR0) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (STU:MVR0) reports promising clinical developments and patent extensions, while navigating funding hurdles to sustain its innovative pipeline.
22 de agosto de 2025
STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin...
20 de agosto de 2025
The European market has shown mixed performance recently, with the pan-European STOXX Europe 600 Index remaining flat over a four-day period, while major indexes such as France's CAC 40 and Italy's FT...
9 de julio de 2025
As European markets continue to navigate a landscape marked by mixed performances and hopes for easing trade tensions, investors are increasingly seeking opportunities in less conventional areas. Penn...
15 de mayo de 2025
Amid escalating trade tensions and the lowest consumer sentiment in nearly three years, European markets have experienced notable volatility. Despite these challenges, the concept of penny stocks rema...
16 de abril de 2025
As European markets navigate the complexities of U.S. trade tariffs and monetary policy uncertainties, the pan-European STOXX Europe 600 Index recently saw a slight decline. Despite these challenges, ...
18 de marzo de 2025
Medivir AB (FRA:MVR0) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (FRA:MVR0) reports significant progress in liver cancer treatment development, despite facing increased clinical costs and market competition.
19 de febrero de 2025
Global markets have recently experienced mixed performances, with major stock indexes showing a combination of gains and declines as the year closed out. For investors looking beyond traditional blue-...
6 de enero de 2025